ImmunityBio (NASDAQ:IBRX) Director Sells $1,691,250.00 in Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 165,000 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. This represents a 5.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

ImmunityBio Price Performance

Shares of IBRX stock opened at $9.55 on Friday. The company has a market capitalization of $9.82 billion, a PE ratio of -25.13 and a beta of 0.16. The firm’s 50-day moving average is $5.12 and its two-hundred day moving average is $3.32. ImmunityBio, Inc. has a 12 month low of $1.83 and a 12 month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. Sell-side analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IBRX. Armistice Capital LLC acquired a new stake in ImmunityBio during the 2nd quarter worth approximately $20,497,000. Heights Capital Management Inc. purchased a new stake in shares of ImmunityBio during the third quarter worth $16,152,000. Vanguard Group Inc. raised its stake in shares of ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after acquiring an additional 5,837,898 shares in the last quarter. State Street Corp boosted its holdings in ImmunityBio by 45.4% in the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after purchasing an additional 5,139,890 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in ImmunityBio by 439.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock valued at $12,182,000 after purchasing an additional 5,012,001 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IBRX. Piper Sandler raised their price objective on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday. HC Wainwright boosted their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a research report on Monday. Finally, Jefferies Financial Group lifted their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ImmunityBio currently has an average rating of “Moderate Buy” and a consensus target price of $12.60.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial rollout drove a multi‑hundred percent revenue jump (reports cite ~671–700% YoY growth), underpinning investor enthusiasm that shares can re-rate on real sales momentum. Read More.
• Positive Sentiment: Q4 results beat expectations — EPS loss narrower than consensus (-$0.06 vs. -$0.08) and revenue ~ $38.3M — providing evidence that commercial sales are scaling. Read More.
• Positive Sentiment: Completed enrollment in a pivotal randomized trial (ANKTIVA + BCG vs BCG alone) for BCG‑naïve non‑muscle invasive bladder cancer — a clear clinical catalyst and potential label/market expansion path. Read More.
• Positive Sentiment: Additional analyst coverage and buy ratings/price‑target increases have reinforced upside narratives (examples include fresh buy ratings and higher longer‑term EPS targets). Read More.
• Neutral Sentiment: Founder/chairman visibility at industry summits raises profile and credibility but is a longer‑term sentiment driver rather than an immediate fundamental change. Read More.
• Neutral Sentiment: Commentary noting a “disconnect” between clinical progress and stock moves highlights that sentiment and headline coverage have amplified price action; suggests volatility may persist. Read More.
• Negative Sentiment: After the strong run, shares pulled back on profit‑taking (reports of an intra‑day drop ~17%), a normal reaction that can amplify short‑term volatility. Read More.
• Negative Sentiment: Insider selling by directors (recent filings show multi‑lot sales at ~$9–$10) may raise questions for some investors about timing and near‑term conviction. Read More.
• Negative Sentiment: Despite momentum, the company remains unprofitable and some broker forecasts trimmed near‑term EPS — keeping execution and valuation risk elevated until sustained profitability or further approvals are proven. Read More.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.